Jul 22, 2021 04:45 PM (GMT+8) · EqualOcean
Wuxi PharmaTech healthcare Fund I L.P. (Wuxi Fund I), a wholly-owned subsidiary of the company, signed a subscription agreement (subscription agreement) with sofinnova partners (management company), which agreed that Wuxi Fund I would subscribe 20 million euro class A shares of sofinnova capital x (Investment Fund), accounting for about 9.7% of the shares of the raised investment fund. The investment fund is a professional private equity investment fund established in accordance with French law, mainly focusing on investing in small and medium-sized enterprises in the field of Life Sciences (especially in the biomedical and medical device industries) all over the world.